Monday November 23 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

YM BioSciences

YM BioSciences is a product development company. Our focus is to advance cancer products along the regulatory and clinical pathways towards commercial approval. YMB does not conduct basic research; rather, our product portfolio is established through a process of careful, rational selection of therapeutics produced in research institutions around the globe. We have one of the broadest oncology portfolios in North America, diversified across technologies, targets and stages of development, to avoid reliance on a single product or platform. YMB is cancer focused. Our current products target solid tumours, which comprise most common types of cancer, and cancer pain. Our current clinical emphasis is on metastatic breast cancer, advanced prostate cancer, unresectable head & neck cancer, specific types of brain tumours, and cancer pain. The large markets for cancer products, combined with typically lower-cost and rapid Phase I and II clinical trials, make this a compelling area on which to focus from a business perspective. YMB currently has four different anti-cancer compounds in clinical development, including tesmilifene, which has completed a 305-patient Phase III clinical trial with positive results. Our business model is to eventually co-develop or partner with pharmaceutical multinationals to manufacture and market our products and offset the cost of pivotal trials. We believe this balanced approach provides the best risk/reward profile for our shareholders.


Contact Details:
5045 Orbitor DriveBuilding 11, Suite 400
Mississauga
Ontario
L4W 4Y4
Canada
Tel:905.629.9761
Fax:905.629.4959
Email:ir@ymbiosciences.com
WWW:

www.ymbiosciences.com/




Loading...

Press Releases on YM BioSciences:

BioPortfolio Logo
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 18th November, 2009 YM BioSciences Inc.
MISSISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
YM BIOSCIENCES REPORTS CYT997 ORAL VASCULAR DISRUPTING AGENT RESULTS PRESENTED AT AACR-NCI-EORTC MEETING 17th November, 2009 YM BioSciences Inc.
MISSISSAUGA, ON, Nov. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 11th November, 2009 YM BioSciences Inc.
MISSISSAUGA, ON, Nov. 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 2nd November, 2009 YM BioSciences Inc.
- Follow-On Results from a Randomized Phase IIb Head & Neck Trial Demonstrate Efficacy of Nimotuzumab Without Severe, Class-Associated Toxicities - MISSISSAUGA, ON, Nov. 2
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 29th October, 2009 YM BioSciences Inc.
MISSISSAUGA, ON, Oct. 29 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of

BioNews Results for YM BioSciences:

YM BioSciences Reports Fiscal First Quarter 2010 Operational and Financial Results
Pharma Live:  Nov 13 2009 3:50AM Matching: ym biosciences
Ym Biosciences Reports Fiscal First Quarter 2010 Operational And Financial Results
Genetic Engineering News:  Nov 12 2009 11:19AM Matching: ym biosciences
Ym Biosciences Reports Fiscal First Quarter 2010 Operational And Financial Results
KSLA:  Nov 12 2009 6:04AM Matching: ym biosciences
Ym Biosciences Reports Fiscal First Quarter 2010 Operational And Financial Results
KOTA Territory News:  Nov 12 2009 11:34AM Matching: ym biosciences
Ym Biosciences Reports Fiscal First Quarter 2010 Operational And Financial Results
Houston Business Journal:  Nov 11 2009 11:55PM Matching: ym biosciences
Promote your company here: BioNewsCast - Press Release Distribution

View more YM BioSciences news.

YM BioSciences (YMI) Financial information Links from Barchart

YMI Quote from from Barchart.com
YMI Chart from from Barchart.com
YMI Profile from from Barchart.com
YMI Opinion from from Barchart.com

View more YM BioSciences finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 480 times since April 2007, the link to the organisation's website has been followed 99 times

Recent Search Terms used to find this page: perspective ym bioscience 2009 | perspective ym bioscience 2009 | .

Search for more companies in Mississauga

Search for more companies in Ontario



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for YM BioSciences

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.